SOURCE: Syneron Medical Ltd.

Syneron Medical Ltd.

June 01, 2011 10:30 ET

Syneron Medical Terminates Shareholder Rights Plan

YOKNEAM, ISRAEL--(Marketwire - Jun 1, 2011) - Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, today announced that its Board of Directors has terminated the shareholder rights plan, effective May 31, 2011.

The shareholder rights plan was adopted on November 11, 2008 after a decline in the market price of Syneron's common stock to ensure that all Syneron shareholders would be treated fairly in the event of any unsolicited takeover of the company. Given the Company's sustained growth, financial strength and the dissatisfaction of its shareholders to the continuation of the shareholder rights plan, Syneron's Board of Directors decided that the protection offered by the shareholder rights plan is no longer warranted.

"The Board takes pride in responsibly serving the best interests of Syneron's shareholders, as well as its commitment to strong corporate governance policies and practices," said Shimon Eckhouse, Chairman of the Board. "At the recent annual meeting, we listened carefully to the viewpoints of our shareholders, including the rejection of the proposal to increase our authorized share capital. We brought that message back to the Board and reconsidered the need for the shareholder rights plan. Much has changed since November 2008 and the concerns that we had then, which motivated the Plan's adoption, are no long as persuasive, so we decided to terminate the Plan."

The amendment to the shareholder rights plan will be filed with the Securities and Exchange Commission on a Form 6-K.

About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets and services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at

Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.

Contact Information